
ENTREPRENEUR & PHILANTHROPIST —
Joseph
Hernandez
BIOTECH EXECUTIVE · VENTURE INVESTOR · HUMANITARIAN · PUBLIC SERVANT
Prolific founder of over twelve healthcare and biopharmaceutical companies. Capital markets architect behind four NYSE and NASDAQ SPACs. Bidder for CITGO Petroleum. Dedicated to advancing global health, scientific discovery, and equal opportunity through entrepreneurship and philanthropy.
12+
COMPANIES FOUNDED
5
ADVANCED DEGREES
$1B+
CAPITAL RAISED
25+
YEAR IN INDUSTRY
ACADEMIC FOUNDATION —
Education &
Scholarship
Joseph Hernandez's academic journey spans four decades of rigorous training across biological sciences, medicine, molecular genetics, epidemiology, finance, and global healthcare leadership — across three world-class institutions.
Bachelor of Science — Neuroscience
Master of Science — Molecular Genetics & Microbiology
MBA — Finance & Entrepreneurship
University of Florida · Phi Kappa Tau

Master of Science — Chronic Disease Epidemiology & Biostatistics
Yale University

Master of Science — Global Healthcare Leadership
University of Oxford

PROFESSIONAL JOURNEY —
A Career Defined by
Discovery
From the halls of Merck to Silicon Valley and back to the startup ecosystem, Joseph Hernandez has built a career at the precise intersection of science, medicine, and entrepreneurial vision — raising over $1 billion in private and public capital across more than a dozen ventures.
1998 – 2004
Merck & Co. · Affymetrix · Digene Corp
Hernandez launched his career at Merck in December 1998, gaining foundational pharmaceutical expertise in sales and marketing. He then moved to Silicon Valley to lead the Marketing Department at Affymetrix, where he oversaw the launch of 12 genomics products. At Digene Corp, he played a pivotal role in advancing the commercialization of the world's first FDA-approved molecular diagnostic test for human papillomavirus (HPV) — work that transformed cervical cancer screening worldwide and ultimately led to the company's $1.6B acquisition by Qiagen in 2007.
2004 – 2009
Innovative Biosensors — Founder & CEO
Founded a clinical-stage diagnostics company based out of MIT's technology ecosystem, developing rapid pathogen detection and diagnostic systems. Earned a Frost & Sullivan Technology Leadership Award in 2005 and the Maryland Daily Record Innovator of the Year in 2006. Has been published in several highly respected scientific journals and presented at numerous scientific meetings.
2010 – 2013
Prolias Technologies — Founder, Chairman & President
An emerging molecular diagnostics company specializing in predictive and prognostic genetic cytology. Prolias developed two commercialization-ready products: THYMIRA™, a miRNA biomarker panel to differentiate malignant from benign thyroid nodules, and ARMIRA™, a non-invasive molecular diagnostic for kidney transplant rejection. Hernandez has served as Chairman since March 2010 and as a director since September 2010.
2010 – 2012
Signal Genetics — President & CEO
Signal Genetics provided detailed, accurate, and personalized diagnostic results to help cancer patients and their healthcare providers determine suitable treatment options. Hernandez served as President and CEO from July 2010 to February 2012.
2012 – 2013
Senior Advisor — Ministry of Foreign Affairs of Denmark
Hernandez served as Senior Advisor to the Danish Ministry of Foreign Affairs, working across export and investment promotion, development policy and cooperation, trade policy, and foreign and security policy — broadening his global perspective beyond the private sector.
2013 – 2017
Microlin Bio — Founder & Chairman
Built a development-stage biotech focused on microRNA-based cancer therapeutics. Entered a landmark license agreement with Ohio State University's cancer microRNA patent portfolio in 2013, targeting prostate, ovarian, colon, and lung cancers. The company went public in 2015.
2014 – 2019
Ember Therapeutics — Founder & Chairman
A publicly traded biopharmaceutical company (OTCMKTS: EMBT) exploring BMP-7's clinical applications for osteoarthritis, insulin resistance reversal, and organ fibrosis in chronic kidney disease, Alport syndrome, obesity, and type 2 diabetes.
2016 – 2019
Sydys Corporation — Founder, Executive Chairman, President & CEO
A biotechnology company focused on developing immuno-oncology products, with Hernandez serving as Executive Chairman, President, CEO, and CFO.
2017 – PRESENT
Blue Water Venture Partners LLC — Founder & Senior Managing Partner
The venture vehicle that manages, finances, and scales Hernandez's growing portfolio of biotech and healthcare companies — creating the partnerships and capital pathways for translational discovery across more than a dozen ventures.
2018 – 2023
Blue Water Vaccines — Founder, Chairman & CEO
In collaboration with the University of Oxford, Hernandez developed a universal influenza vaccine and successfully led the company to a NASDAQ IPO in February 2022, ringing the closing bell on February 18, 2022. The company later expanded its ocnology focus with Entadfi, an FDA-approved therapy for benign prostatic hyperplasia that combines finasteride and tadalafil. Hernandez served as founder and chairman through August 2023.
2020
Noachis Terra — Founder
A COVID-19 vaccine biotech acquired by Oragenics within five months of incorporation — a testament to the speed and precision of Hernandez's company-building model.
2023 – PRESENT
Expanding the Frontier
Hernandez continues to push scientific and technological boundaries with Temple Street Biotech (Alzheimer's research), Eternity Biotech (longevity, with Yale), Perseus Therapeutics (hair restoration, in partnership with Duke University), and Energia Power Systems (sodium-ion and lithium-ion battery technology, developed out of Stanford University's research ecosystem).
GOVERNANCE —
Board &
Leadership Positions
2006 – 2012
Shady Grove Hospital
Board Member
2013 – 2017
Microlin Bio
Chairman
2021 – 2022
Clarus Therapeutics
Executive Board Member & Audit / Compensation Committee
2025 – PRESENT
Blue Water Acquisition Corp IV
Chairman
2007 – 2011
Tech Council of Maryland
Executive Board Member
2014 – 2019
Ember Therapeutics
Chairman
2021 – 2022
Blue Water Acquisition Corp II
Chairman
2026 – PRESENT
Yale Graduate School Alumni Association Board (GSAAB)
Member
2013 – 2017
MdBio, Inc.
Board Member — Mid-Atlantic Life Sciences Industry Association
2020 – 2021
Blue Water Acquisition Corp
Chairman
2025
Blue Water Acquisition Corp III
Chairman
GIVING BACK —
A Commitment to
Lasting Impact
Joseph Hernandez's philanthropic footprint is as distinguished as his professional legacy — spanning academic endowment, scientific exploration, and the advancement of equality in sport.


University of Florida — $10M Endowment
The largest donation received from a donor under 50 in the university's history. Hernandez directed funding toward Hernandez Hall and later pivoted toward scholarship programs in response to the COVID-19 pandemic.




Oxford Dodo Genome Project
Funded the full genome sequencing of the dodo at the University of Oxford — advancing scientific understanding of the genetic mechanisms behind flightlessness in extinct island birds.




Women in
Polo
Since 2021, Hernandez has funded multiple all-female polo teams, challenging the male-dominated conventions of the sport and championing pathways for women athletes.
RECOGNITION —
Awards &
Honors
2005
Technology Leadership Award
FROST & SULLIVAN · INNOVATIVE BIOSENSORS INC
2006
Innovator of the Year
MARYLAND DAILY RECORD · INNOVATIVE BIOSENSORS INC
2017
Gran Caiman Award
UNIVERSITY OF FLORIDA ASSOCIATION OF HISPANIC ALUMNI · FOR PHILANTHROPIC CONTRIBUTION TO UF
CAPITAL MARKETS —
Blue Water SPACs, CITGO &
Global Acquisitions
Hernandez has built one of the most prolific SPAC platforms in healthcare and technology, while simultaneously expanding Blue Water Venture Partners into consumer brands and global energy — with a $10 billion bid for CITGO Petroleum.
2020 – 2021
Blue Water Acquisition Corp. I — NASDAQ
Founded in 2020, Blue Water Special Acquisition Corp. merged with Clarus Therapeutics Holdings Inc. in April 2021, forming a publicly listed company focused on developing androgen and metabolic therapies for unmet needs in men and women.
2021 – 2022
Blue Water Acquisition Corp. II
In October 2021, Hernandez founded his second SPAC, Blue Water Acquisition Corp. II, structured as a $75 million IPO focused on biotech and healthcare technology. The vehicle was slated to list on NASDAQ under the ticker BWTRU. In August 2022, due to shifting market conditions, Hernandez elected to withdraw BWAC II prior to its public debut.
JUNE 2025
Blue Water Acquisition Corp. III — NASDAQ: BLUWU ($253M IPO)
Hernandez successfully led Blue Water Acquisition Corp. III to the public markets in June 2025, raising $253 million in its NASDAQ IPO (ticker: BLUWU) — 25.3 million units priced at $10 each. The vehicle was positioned to target companies at the intersection of biotechnology, healthcare services, and artificial intelligence. It reached a market capitalization of $325 million. In June 2025, Hernandez and his team rang the opening bell at NASDAQ.
SEPTEMBER 2025
Blue Water Acquisition Corp. III — $10B Bid for CITGO Petroleum
Hernandez deployed Blue Water Acquisition Corp. III as the vehicle for a landmark $10 billion bid to acquire PDV Holding Inc., the parent company of CITGO Petroleum Corp., in a Delaware court-supervised auction. The bid was the highest offer received, and in Hernandez's words, was designed to provide creditors "immediate recovery and the opportunity to participate in the future of Citgo as a U.S. public company." In September 2025, Blue Water received court authorization to enter a non-disclosure agreement with the Special Master and access the confidential data room — advancing formally in the process. The bid's purpose: preventing hedge fund or foreign control of a critical U.S. energy asset while protecting American energy independence. For Hernandez, a Cuban-born entrepreneur whose father was imprisoned under Castro, the mission of returning CITGO to American public ownership carried profound personal meaning.
DECEMBER 2025
Blue Water Acquisition Corp. IV — NYSE: BWIV ($130M IPO)
In March 2026, Hernandez brought Blue Water Acquisition Corp. IV to the public markets through a $130 million IPO. Listed on the New York Stock Exchange under the ticker BWIV.U, the vehicle builds on the approach developed across earlier Blue Water SPACs, with an emphasis on companies applying artificial intelligence and other advanced technologies to create meaningful value. While areas such as healthcare, data infrastructure, and digital platforms remain key points of interest, the company continues to evaluate opportunities across a wide range of industries and sectors. On April 1, 2026, Hernandez and the Blue Water team rang the Closing Bell at the NYSE in New York City, marking an important moment for the platform’s next chapter.
CIVIC LEADERSHIP —
Political
Campaigns
In 2025, Joseph Hernandez transitioned from entrepreneur to civic candidate — applying his record of company-building, fiscal discipline, and results-oriented leadership to the arena of public service. His campaigns have drawn national media attention and earned formal nominations from multiple major parties.
2025 — NYC MAYORAL RACE
Independent Candidate for Mayor of New York City
Quality of Life Party · Reform Party
Hernandez officially launched his mayoral campaign on July 1, 2025 at a press conference in front of the New York Stock Exchange — a deliberate symbol of his pro-growth, pro-capitalism platform. He was joined at the launch by the Bodega and Small Business Group, the largest organized network of bodega owners in the city, who announced their formal endorsement on the spot. Running on three core priorities — public safety (hiring 10,000 additional police officers), housing affordability through office-to-residential conversion, and AI-driven government efficiency — his campaign gathered nearly 15,000 valid petition signatures, nearly four times the legal minimum. He was certified by the NYC Board of Elections and appeared on the November 2025 general election ballot under the Quality of Life Party, earning additional endorsement from the Reform Party of New York State and the national Reform Party of the United States. He formally challenged debate organizers for excluding the only Hispanic candidate from the general election stage, citing FCC fairness regulations.
2026 — NY STATE COMPTROLLER RACE
Republican & Conservative Party Nominee
Two Ballot Lines · November 3, 2026
Hernandez announced his candidacy for New York State Comptroller in November 2025. On February 10–11, 2026, he was unanimously nominated by the New York State Republican Party at its convention in Garden City, Nassau County, earning support from county party chairs across the state. On February 14, 2026, the New York State Conservative Party also unanimously nominated him — ensuring he will appear on both the Republican (Row B) and Conservative (Row C) ballot lines in the November 3, 2026 General Election.
He is challenging 19-year incumbent Tom DiNapoli, the longest-serving non-congressional statewide officeholder in New York history. His platform: AI-powered real-time auditing of every state agency, a $10 billion innovation investment fund within the pension system, strict enforcement of the property tax cap, full oversight of the MTA's $46 billion debt, and accountability for New York's $265 billion annual budget.
PARTY NOMINATIONS & ENDORSEMENTS
2025 NYC MAYORAL CAMPAIGN
Bodega and Small Business Group
(Endorsement)
National Supermarket Association
(Endorsement)
2026 NYC STATE COMPTROLLER CAMPAIGN
Republican Party of New York State
(Party Nomination – Unanimous)
Conservative Party of New York State
(Party Nomination – Unanimous)
PUBLIC DISCOURSE —
Interviews &
Media
Hernandez has participated extensively in interviews, podcasts, congressional hearings, and panel discussions spanning biotechnology, global health policy, vaccine development, entrepreneurship, and civic affairs. In 2009, he provided congressional testimony before the House Subcommittee on Contracting and Technology. His 2025–2026 campaigns further elevated his national media profile.
BIOTECH & HEALTHCARE —
U.S. CONGRESS 2009
SCHWAB NETWORK 2021
HEALTH BUSINESS GROUP 2021
EMPOWERED PATIENT PODCAST 2022
BIOTECH NATION 2023
CONTAGION LIVE 2020
BIOTECH 2050 PODCAST MAR 2021
ISTANBUL ECONOMY SUMMIT 2022
LUXURY MAGAZINE 2022
DRUG TARGET REVIEW 2023
CIVIC AFFAIRS & PUBLIC POLICY —
NY1 INSIDE CITY HALL AUG 2025
QUEENS LEDGER JUL 2025
FOX NEWS DIGITAL AUG 2025
TELEVISION - COMPTROLLER CAMPAIGN 2025-2026 —
SPECTRUM NEWS NY1 (TV) NOV 20, 2025
WBNG-TV (CBS BINGHAMTON) DEC 18, 2025
WRGB CBS6 ALBANY (TV) FEB 12, 2026
PIX11 / NEXSTAR (TV) FEB 2026
WBNG-TV (CBS BINGHAMTON) DEC 10, 2025
WBNG-TV (CBS BINGHAMTON) JAN 28, 2026
NY STATE OF POLITICS (SPECTRUM) MAR 2026
RADIO - COMPTROLLER & MAYORAL CAMPAIGNS —
77 WABC RADIO (NEW YORK) 2026
AMERICA OUT LOUD TALK RADIO MAR 2026
CAPITOL PRESS (WAMC/NPR ALBANY) DEC 2025
PRINT & DIGITAL - COMPTROLLER CAMPAIGN —
THE RIVER REPORTER FEB 2026
THE ALGEMEINER FEB 11, 2026
NEW YORK FAMILIES FEB 2026
SOUTH SHORE PRESS FEB 2026
OBSERVER TODAY FEB 2026
BEYOND THE BOARDROOM —
The Man
Behind the Mission
Born in Camagüey, Cuba, the son of a political prisoner, Joseph Hernandez came to the United States as a seven-year-old refugee - a foundation that informs his deep sense of purpose, resilience, and responsibility to community.
Outside of his professional endeavors, Hernandez is a devoted father of three.
Building companies, advancing science, and improving lives through innovation and public service









